Geoffrey von Maltzahn


Geoffrey von Maltzahn joined Flagship Pioneering in 2009 and serves as partner. He is an inventor, entrepreneur, CEO, and the co-founder of multiple groundbreaking companies in healthcare, nutrition and agriculture.

Geoffrey has co-founded companies that have, in aggregate, achieved over $4 billion in public and private market capitalization. Through his role in Flagship VentureLabs, these include Kaleido Biosciences, Indigo Agriculture, Seres Therapeutics (NASDAQ: MCRB), and Axcella Health which are, respectively, pioneering novel chemistries to drive the human microbiome; plant microbiome products for crop improvement; the first microbiome therapeutics; and amino acid-based drugs. Prior to joining Flagship, Geoffrey co-founded Sienna Biopharmaceuticals (NASDAQ: SNNA), a leading clinical-stage biopharmaceutical company in medical dermatology.

Geoffrey currently serves as chief innovation officer and director of Kaleido Biosciences and recently served as its chief executive officer, where he led the company from inception to building the first industrialized drug discovery platform for the human microbiome and launched multiple human studies. Geoffrey also currently serves as chief innovation officer of Indigo and recently also served as president of Indigo, where he led the development of the company’s plant microbiome platform, the growth of the world’s largest plant microbiome database, and the discovery of the company’s first commercial products: Indigo Cotton, Indigo Wheat, Indigo Corn, and Indigo Soy. Previously, Geoffrey was the chief technology officer of Seres Therapeutics, where he led the discovery of SER-109 and built out the company’s discovery platform. He has also served as vice president of discovery of Axcella, where he led the discovery of two therapeutic products in human trials.

Geoffrey has deep expertise in the microbiome, bioengineering and nanotechnology, and he has been recognized with numerous patent grants, awards, and publications. He is an inventor on over 200 patent applications and patents, and he has co-authored more than 20 peer-reviewed publications. Geoffrey has received a number of awards and honors, including: Business Insider’s 30 Biotech Leaders Under 40; the prestigious Lemelson-MIT Student Prize, awarded to the most innovative student at MIT; the National Inventors Hall of Fame Graduate Student Prize; the Biomedical Engineering Society Graduate Research Award; the Harvard-MIT Martha Gray Prize; and the Randolph G. Wei Award, which is awarded for MIT’s most outstanding contribution at the interface of life sciences and engineering undergraduate research. Geoff and his inventions have been profiled by Forbes, the Economist, CNN, Scientific American, Popular Sciences, MIT Technology Review, and many others.

Geoffrey was awarded a Ph.D. in biomedical engineering and medical physics from MIT under the mentorship of Sangeeta N. Bhatia, M.D., Ph.D.; a M.S. in bioengineering from the University of California, San Diego; and a S.B. in chemical engineering from MIT.

Geoffrey von Maltzahn